The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy
摘要：
Background Colorectal carcinoma (CRC) with CpG island methylator phenotype (CIMP) is recognized as a distinct subgroup of CRC, and CIMP status affects prognosis and response to chemotherapy. Identification of CIMP status in CRC is important for proper patient management. In Eastern countries, however, the clinicopathologic and molecular characteristics and prognosis of CRCs with CIMP are still unclear. Methods A total of 245 patients who underwent their first surgical resection for sporadic CRC were enrolled and CIMP status of the CRCs was determined using the quantitative MethyLight assay. The clinicopathologic and molecular characteristics were reviewed and compared according to CIMP status. In addition, the three-year recurrence-free survival (RFS) of 124 patients with stage II or stage III CRC was analyzed in order to assess the effectiveness of fluoropyrimidine-based adjuvant chemotherapy with respect to CIMP status. Results CIMP-high CRCs were identified in 34 cases (13.9%), and were significantly associated with proximal tumor location, poorly differentiated carcinoma, mucinous histology, and high frequencies of BRAF mutation, MGMT methylation, and MSI-high compared to CIMP-low/negative carcinomas. For patients with stage II or III CIMP-low/negative CRCs, no significant difference was found in RFS between those undergoing surgery alone and those receiving surgery with fluoropyrimidine-based adjuvant chemotherapy. However, for patients with CIMP-high CRCs, patients undergoing surgery with fluoropyrimidine-based adjuvant chemotherapy (n = 17; three-year RFS: 100%) showed significantly better RFS than patients treated with surgery alone (n = 7; three-year RFS: 71.4%) (P = 0.022). Conclusions Our results suggest that selected patients with CIMP-high CRC may benefit from fluoropyrimidine-based adjuvant chemotherapy with longer RFS. Further large scale-studies are required to confirm our results.
展开
DOI：
10.1186/1471-2407-11-344
被引量：
年份：
2011
Elsevier
(全网免费下载)
Elsevier
Springer
(全网免费下载)
Springer
EBSCO
查看更多
Semantic Scholar
Semantic Scholar
(全网免费下载)
dx.doi.org
BioMed Central
(全网免费下载)
BioMed Central
(全网免费下载)
BioMed Central
Europe PMC
(全网免费下载)
BioMed Central
NCBI
BioMed Central
(全网免费下载)
NCBI
(全网免费下载)
Europe PMC
NCBI
OALib
ResearchGate
ResearchGate
(全网免费下载)
ProQuest
EBSCO
Citeseer
(全网免费下载)
EBSCO
mailer.oalib.net
mendeley.com
core.ac.uk
(全网免费下载)
ajconline.org
ejinme.com
giejournal.org
(全网免费下载)
jada.ada.org
gastrojournal.org
gooa.las.ac.cn
(全网免费下载)
gastrojournal.org
(全网免费下载)
paperity.org
redjournal.org
(全网免费下载)
学术范
(全网免费下载)
doaj.org
neoplasia.com
pubfacts.com
thegreenjournal.com
(全网免费下载)
deepdyve.com
cghjournal.org
ejcancer.com
(全网免费下载)
学术范
goldjournal.net
(全网免费下载)
mysciencework.com
core.kmi.open.ac.uk
science-open.com
biomedsearch.com
(全网免费下载)
biomedsearch.com
cebp.aacrjournals.org
cghjournal.org
(全网免费下载)
scienceopen.com
(全网免费下载)
clinicalkey.com
science-open.com
(全网免费下载)
go.galegroup.com
bvsalud.org
scienceopen.com
jpeds.com
(全网免费下载)
goldjournal.net
jacionline.org
BioMed Central
(全网免费下载)
core.ac.uk
Elsevier
(全网免费下载)
Springer
(全网免费下载)
Semantic Scholar
(全网免费下载)
Europe PMC
(全网免费下载)
BioMed Central
(全网免费下载)
NCBI
(全网免费下载)
BioMed Central
(全网免费下载)
BioMed Central
(全网免费下载)
ResearchGate
(全网免费下载)
Citeseer
(全网免费下载)
giejournal.org
(全网免费下载)
redjournal.org
(全网免费下载)
学术范
(全网免费下载)
jpeds.com
(全网免费下载)
goldjournal.net
(全网免费下载)
cghjournal.org
(全网免费下载)
science-open.com
(全网免费下载)
gastrojournal.org
(全网免费下载)
scienceopen.com
(全网免费下载)
ejcancer.com
(全网免费下载)
thegreenjournal.com
(全网免费下载)
biomedsearch.com
(全网免费下载)
gooa.las.ac.cn
(全网免费下载)
BioMed Central
(全网免费下载)
core.ac.uk
(全网免费下载)
通过文献互助平台发起求助，成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
